Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.
Colorado. Maria M; Gomez Miranda. Jose J; Arias-Morales. Carlos E CE
Key Findings
- Tirzepide can cause palpitations in some users
- Musculoskeletal pain and headaches were observed after tirzepide administration
- Post‑marketing safety monitoring is essential to catch rare or unexpected adverse events
Practical Outcomes
- If you’re using tirzepide, watch for heart‑racing, muscle/joint pain, or headaches and report them. Consider lowering the dose or stopping if symptoms are severe, and discuss any new side‑effects with a healthcare professional.
Summary
The paper reports three people who felt heart‑palpitations, joint‑muscle aches, and headaches after starting tirzepide, a new weight‑loss drug, suggesting these side‑effects may be more common than thought.
Abstract
Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separately. The case reports presented here, detailing palpitations, musculoskeletal pain, and headaches following tirzepatide administration, raise important questions about the drug's postmarketing safety profile.
Study Information
pubmed
2025
2025-08-29T00:00:00.000Z
10.1210/jcemcr/luaf195
1
7